Switch theme
Sign up to access all valuation multiples
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
1980
1.4K+
LTM Revenue $2.3B
LTM EBITDA $480M
$6.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sarepta Therapeutics has a last 12-month revenue of $2.3B and a last 12-month EBITDA of $480M.
In the most recent fiscal year, Sarepta Therapeutics achieved revenue of $1.9B and an EBITDA of $317M.
Sarepta Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sarepta Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.9B | XXX | XXX | XXX |
| Gross Profit | $793M | $1.1B | XXX | XXX | XXX |
| Gross Margin | 64% | 57% | XXX | XXX | XXX |
| EBITDA | -$454M | $317M | XXX | XXX | XXX |
| EBITDA Margin | -36% | 17% | XXX | XXX | XXX |
| Net Profit | -$703M | -$536M | XXX | XXX | XXX |
| Net Margin | -57% | -28% | XXX | XXX | XXX |
| Net Debt | $578M | $810M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 29, 2025, Sarepta Therapeutics's stock price is $62.
Sarepta Therapeutics has current market cap of $6.0B, and EV of $6.0B.
See Sarepta Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.0B | $6.0B | XXX | XXX | XXX | XXX | $2.68 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of April 29, 2025, Sarepta Therapeutics has market cap of $6.0B and EV of $6.0B.
Sarepta Therapeutics's trades at 2.7x LTM EV/Revenue multiple, and 12.6x LTM EBITDA.
Analysts estimate Sarepta Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sarepta Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $6.0B | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | 19.0x | XXX | XXX | XXX |
| P/E | 25.7x | XXX | XXX | XXX |
| P/E/Growth | 0.2x | XXX | XXX | XXX |
| EV/FCF | -17.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSarepta Therapeutics's NTM/LTM revenue growth is 44%
Sarepta Therapeutics's revenue per employee for the last fiscal year averaged $1.4M, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Sarepta Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sarepta Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sarepta Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 53% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -170% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 61% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 42% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 72% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sarepta Therapeutics acquired XXX companies to date.
Last acquisition by Sarepta Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Sarepta Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sarepta Therapeutics founded? | Sarepta Therapeutics was founded in 1980. |
| Where is Sarepta Therapeutics headquartered? | Sarepta Therapeutics is headquartered in United States of America. |
| How many employees does Sarepta Therapeutics have? | As of today, Sarepta Therapeutics has 1.4K+ employees. |
| Who is the CEO of Sarepta Therapeutics? | Sarepta Therapeutics's CEO is Mr. Douglas S. Ingram,Esq.. |
| Is Sarepta Therapeutics publicy listed? | Yes, Sarepta Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Sarepta Therapeutics? | Sarepta Therapeutics trades under SRPT ticker. |
| When did Sarepta Therapeutics go public? | Sarepta Therapeutics went public in 1997. |
| Who are competitors of Sarepta Therapeutics? | Similar companies to Sarepta Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sarepta Therapeutics? | Sarepta Therapeutics's current market cap is $6.0B |
| What is the current revenue of Sarepta Therapeutics? | Sarepta Therapeutics's last 12-month revenue is $2.3B. |
| What is the current EBITDA of Sarepta Therapeutics? | Sarepta Therapeutics's last 12-month EBITDA is $480M. |
| What is the current EV/Revenue multiple of Sarepta Therapeutics? | Current revenue multiple of Sarepta Therapeutics is 2.7x. |
| What is the current EV/EBITDA multiple of Sarepta Therapeutics? | Current EBITDA multiple of Sarepta Therapeutics is 12.6x. |
| What is the current revenue growth of Sarepta Therapeutics? | Sarepta Therapeutics revenue growth between 2023 and 2024 was 53%. |
| Is Sarepta Therapeutics profitable? | Yes, Sarepta Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
